---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-062155"
form_type: "8-K"
ticker: "PLYX"
cik: "0002075320"
company_name: "Polaryx Therapeutics, Inc."
filed_at: "2026-05-28T20:31:45+00:00"
generated_at: "2026-05-28T20:34:01.278201+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Polaryx closes $10M PIPE at ~$4.00/share to fund Phase 2 SOTERIA basket trial

## Summary
- Private placement of 2,502,696 common shares at avg $4.00/share for $10M gross proceeds to ~35 investors.
- Largest stockholder MStone Partners Healthcare purchased 88,453 shares ($360k) in the offering.
- Net proceeds will fund initiation of Phase 2 SOTERIA trial (CLN2, CLN3, Krabbe, Sandhoff) and extend cash runway through Q2 2027.
- No resale registration statement will be filed; shares issued under Section 4(a)(2) and Regulation S exemption.
- FDA Fast Track Designation already in place for all four planned LSD indications.

## SEC filing metadata
- accession: 0001213900-26-062155
- form_type: 8-K
- ticker: PLYX
- cik: 0002075320
- company_name: Polaryx Therapeutics, Inc.
- filed_at: 2026-05-28T20:31:45+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/0001213900-26-062155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/ea0291692-8k_polaryx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-062155
- JSON: https://secwatch.observer/filing/0001213900-26-062155.json
- Plain text: https://secwatch.observer/filing/0001213900-26-062155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.